Companies › Taejoon Pharmaceutical
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 3; Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CTO0308 Ophthalmic myopia progression inhibitor | – | Phase 3 | Myopia | Apr 2027 |
| TJO-087 | – | Phase 2 | Dry Eye Syndrome (DES) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07810972 | TJO-087 | Phase 2 | Dry Eye Syndrome (DES) | Ophthalmology | Dec 2026 |
| NCT07790640 | CTO0308 | Phase 3 | Myopia | Ophthalmology | Apr 2027 |
No annotated target.
–
Huons Andover Research Eye Institute SANGMYUNG innovation Vantage Biosciences Tourmaline Bio, Inc., a Novartis Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.